N,N,N-Trimethyl-p-carboxyphenylammonium | 35115-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N,N-Trimethyl-p-carboxyphenylammonium
• 英文别名: 4-Carboxyphenyl-trimethylammoniumkation；(4-carboxyphenyl)-trimethylazanium
• CAS: 35115-20-9
• 化学式: C₁₀H₁₄NO₂
• 分子量: 180.227
• InChiKey: XPULRSZBSCQUTI-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  叔丁基过氧化氢 、 [4-(Hydroxymethyl)phenyl]-trimethylazanium 在 rhodium(III) chloride hydrate 作用下， 以 水 、 乙腈 为溶剂， 生成 、 4-trimethylammoniumbenzaldehyde 、 N,N,N-Trimethyl-p-carboxyphenylammonium 、 Trimethyl-[4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]azanium
  参考文献：
  名称：

  通过纸喷雾质谱法监测的表面醇氧化：钌作为催化剂的作用。

  摘要：

  本文采用纸喷雾电离质谱 (PS-MS) 作为研究表面催化过程的便捷平台，即由钌盐诱导的醇的氧化。带标签的苯甲醇 1 (m/z 166)，用作合适的原型起始底物，在三氯化钌 (RuCl3) 催化的表面过程中被叔丁基过氧化氢 (TBHP) 快速氧化。PS(+)-MS 揭示了酒精 1 氧化产物的形成。RuCl3 和 TBHP 在此过程中起着至关重要的作用，因为当其他金属（铂、钯和铁）的盐和另一种氧化剂（过氧化氢） ) 被使用，没有观察到反应。此外，紫外线辐射和加热会加速表面醇 1 的氧化。最后，

  DOI：

  10.1021/jasms.1c00125

文献信息

• 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
  申请人：——

  公开号：US20040002513A1

  公开（公告）日：2004-01-01

  The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the &agr;7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

  本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷类化合物，制备这些化合物的方法以及使用这些化合物进行治疗的方法。这些氮杂双环烷通常是氮杂双环庚烷、氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基是一个5-或6-成员环杂芳基，优选是3-吡啶基和5-嘧啶基，烷基通常是C1-4烷基。1-氮杂双环烷的3-位取代基是一个含有羰基的基团，例如酰胺、碳酸酯、脲、硫代酰胺、硫代碳酸酯、硫脲或类似功能基团。这些化合物在尼古丁型乙酰胆碱受体(nAChRs)上表现出活性，特别是α7 nAChR亚型，并且对调节神经递质传递和与神经递质有关的配体释放具有用处。还公开了用于预防或治疗中枢神经系统（CNS）疾病等疾病和疾病的方法，这些疾病和疾病以正常神经递质传递的改变为特征。还公开了用于治疗炎症、自身免疫疾病、疼痛和过度新生血管化的方法，例如与肿瘤生长相关的新生血管化。
• 3-Substituted-2(Arylalkyl)-1-Azabicycloalkanes and Methods of Use Thereof
  申请人：Mazurov A. Anatoly

  公开号：US20060247270A1

  公开（公告）日：2006-11-02

  The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

  本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷化合物，制备该化合物的方法以及使用该化合物的治疗方法。氮杂双环烷通常是氮杂双环庚烷、氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基基团是5-或6-成员环异芳基，优选为3-吡啶基和5-嘧啶基团，烷基通常为C1-4烷基。1-氮杂双环烷的3-位取代基是含有羰基基团的基团，例如酰胺、氨基甲酸酯、脲、硫酰胺、硫代氨基甲酸酯、硫脲或类似的官能团。该化合物在尼古丁乙酰胆碱受体(nAChRs)上表现出活性，特别是α7 nAChR亚型，并对调节神经递质和参与神经递质释放的配体具有用处。还公开了预防或治疗中枢神经系统(CNS)疾病等条件和障碍的方法，这些疾病的特征是正常神经递质发生改变。还公开了治疗炎症、自身免疫性疾病、疼痛和过度新生血管化的方法，例如与肿瘤生长有关的新生血管化。
• Heteroaryl-Substituted Diazatricycloalkanes and Methods of Use Thereof
  申请人：Mazurov Anatoly

  公开号：US20070197579A1

  公开（公告）日：2007-08-23

  The present invention relates to amide and urea derivatives of heteroaryl-substituted diazatricycloalkanes, pharmaceutical compositions including the compounds, methods of preparing the compounds, and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the α7 nAChR subtype by administering one or more of the compounds to treat or prevent disorders mediated by the α7 nAChR subtype. The diazatricycloalkanes typically consist of a 1-azabicyclooctane fused to pyrrolidine ring. The substitutent heteroaryl groups are 5- or 6-membered ring heteroaromatics, such as 3-pyridinyl and 5-pyrimidinyl moieties, which are attached directly to the diazatricycloalkane. The secondary nitrogen of the pyrrolidine moiety is substituted with an arylcarbonyl (amide type derivative) or an arylaminocarbonyl (N-arylcarbamoyl) (urea type derivative) group. The compounds are beneficial in therapeutic applications requiring a selective interaction at certain nAChR subtypes. That is, the compounds modulate the activity of certain nAChR subtypes, particularly the α7 nAChR subtype, and do not have appreciable activity toward muscarinic receptors. Radiolabeled versions of the compounds can be used in diagnostic methods.

  本发明涉及杂环取代的二氮杂三环烷的酰胺和脲衍生物、包括这些化合物的药物组合物、制备这些化合物的方法以及使用这些化合物的治疗方法。更具体地说，治疗方法涉及通过给予一种或多种化合物来调节α7 nAChR亚型的活性，以治疗或预防由α7 nAChR亚型介导的疾病。二氮杂三环烷通常由1-氮杂双环辛烷与吡咯烷环融合而成。取代杂环基团是5-或6-成员环杂芳基，例如3-吡啶基和5-嘧啶基，直接连接到二氮杂三环烷上。吡咯烷基团的次要氮原子被芳基羰基（酰胺型衍生物）或芳基氨基羰基（N-芳基氨基甲酰）（脲型衍生物）基团取代。这些化合物在需要选择性相互作用于某些nAChR亚型的治疗应用中具有益处。也就是说，这些化合物调节某些nAChR亚型的活性，特别是α7 nAChR亚型，并且对于肌动蛋白受体没有明显的活性。这些化合物的放射标记版本可用于诊断方法。
• 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF
  申请人：Mazurov Anatoly A.

  公开号：US20080138287A1

  公开（公告）日：2008-06-12

  The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds, and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

  本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷类化合物、制备该类化合物的方法以及使用该类化合物的治疗方法。氮杂双环烷通常是氮杂双环庚烷、氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基是一个5-或6-成员环杂芳基，优选是3-吡啶基和5-嘧啶基，烷基通常是C1-4烷基。1-氮杂双环烷的3-位取代基是一种含有羰基基团的基团，例如酰胺、氨基甲酸酯、脲、硫酰胺、硫代氨基甲酸酯、硫脲或类似的官能团。该化合物在尼古丁乙酰胆碱受体(nAChRs)上表现出活性，特别是α7 nAChR亚型，并且对于调节神经递质和神经递质参与的配体的释放是有用的。还公开了预防或治疗条件和疾病的方法，包括中枢神经系统(CNS)疾病，这些疾病的特征是正常神经递质的改变。还公开了治疗炎症、自身免疫性疾病、疼痛和过度新血管生成的方法，例如与肿瘤生长相关的新血管生成。
• THYMIDINE ANALOGS FOR IMAGING
  申请人：SRINIVASAN Ananth

  公开号：US20080170993A1

  公开（公告）日：2008-07-17

  The present invention relates to nucleoside analogues and more particularly to labeled nucleoside analogues. It has been found new thymidine analogues can be stably labeled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and/or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.

  本发明涉及核苷类似物，更具体地涉及标记的核苷类似物。已发现新的胸腺嘧啶类似物可以稳定地标记为可检测的标记基团。此外，本发明还涉及制备上述化合物的方法以及利用这些化合物进行肿瘤细胞的诊断成像和/或增殖性疾病的治疗的用途。此外，本发明还涉及正电子发射剂的制备和应用于正电子发射断层扫描（PET）的用途。还公开了一种试剂盒。